Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin

Related Experiment Video

Updated: Mar 2, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Emmanouela Kampouraki1, Peter J Avery2, Tina Biss3

  • 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.

Pediatric Blood & Cancer
|May 19, 2017
PubMed

Insights

Children on warfarin therapy have low vitamin K levels, influenced by their CYP4F2 genotype. This may impact bone and vascular health during development.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Vitamin K is crucial for blood clotting, bone health (osteocalcin), and vascular health (matrix-Gla protein).
  • Cytochrome P450 4F2 (CYP4F2) enzyme plays a role in vitamin K metabolism.
  • Genetic variations in CYP4F2 may alter vitamin K availability.

Purpose of the Study:

  • To investigate the relationship between CYP4F2 genotype and vitamin K levels in children undergoing chronic warfarin therapy.
  • To explore the potential impact of genotype-influenced vitamin K levels on bone and vascular health in this pediatric population.

Main Methods:

  • Genotyping for CYP4F2 variants in children on chronic warfarin therapy.
  • Measurement of vitamin K levels in the study cohort.
  • Correlation analysis between CYP4F2 genotype, vitamin K status, and clinical outcomes (bone/vascular health).

Main Results:

  • Children on chronic warfarin therapy exhibited reduced vitamin K levels.
  • Vitamin K levels were significantly associated with specific CYP4F2 genotypes.
  • The findings suggest a link between CYP4F2 genotype, vitamin K availability, and potential long-term health effects.

Conclusions:

  • CYP4F2 genotype influences vitamin K status in children receiving long-term warfarin treatment.
  • Sustained low vitamin K levels, potentially mediated by CYP4F2 genotype, may pose risks to bone development and vascular health in these children.

Keywords:
CYP4F2paediatricsvitamin Kwarfarin

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
53
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
5.8K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387